Exo1 (Synonyms: Exocytic Inhibitor 1, NSC 214045) |
Catalog No.GC15751
One-Click Copy Product Info
|
Golgi-ER traffic inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 461681-88-9;75541-83-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IC50: about 20 μM for exocytosis
Exo1 is a chemical inhibitor of the exocytic pathway.
The development of a cellular organism is mainly controlled at the transcriptional level but it was also shown to require the transport of membrane and proteins via the exocytic pathway to the plasma membrane and the extracellular medium.
In vitro: A Previous study using phenotypic screen to search for drug-like molecules that could interfere with specific steps in membrane traffic. Screening resulted in the identification of Exo1, which could induce a rapid collapse of the Golgi to the endoplasmic reticulum, therefore inhibiting the traffic emanating from the endoplasmic reticulum acutely. In addition, similar to Brefeldin A (BFA), Exo1 could induce the quick release of ADP-ribosylation factor (ARF) 1 from Golgi membranes but had minimal effect on the organization of the trans-Golgi network. These data suggested that Exo1 acted by a different mechanism from BFA. However, unlike BFA, Exo1 could not induce the ADP-ribosylation of CtBPBars50 and could not interfere with the activity of guanine nucleotide exchange factors neither. Thererfore, Exo1 allowed the fatty acid exchange activity of Bars50 to be distinguished from ARF1 activity [1].
In vivo: Currently, there is no animal data reported.
Clinical trial: Up to now, Exo1 is still in the preclinical development stage.
Reference:
[1] Feng Y,Yu S,Lasell TK,Jadhav AP,Macia E,Chardin P,Melancon P,Roth M,Mitchison T,Kirchhausen T. Exo1: a new chemical inhibitor of the exocytic pathway. Proc Natl Acad Sci U S A.2003 May 27;100(11):6469-74.
| Cas No. | 461681-88-9;75541-83-2 | SDF | |
| Synonyms | Exocytic Inhibitor 1, NSC 214045 | ||
| Chemical Name | methyl 2-(4-fluorobenzamido)benzoate | ||
| Canonical SMILES | FC1=CC=C(C=C1)C(NC2=CC=CC=C2C(OC)=O)=O | ||
| Formula | C15H12FNO3 | M.Wt | 273.26 |
| Solubility | <6.83mg/ml in ethanol; <27.33mg/ml in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6595 mL | 18.2976 mL | 36.5952 mL |
| 5 mM | 731.9 μL | 3.6595 mL | 7.319 mL |
| 10 mM | 366 μL | 1.8298 mL | 3.6595 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)